<DOC>
	<DOC>NCT02848170</DOC>
	<brief_summary>Phase 3 study to examine the relation between antihypertensive effect and baseline factors exploratively, compared to olmesartan medoxomil in patients with essential hypertension.</brief_summary>
	<brief_title>Study of CS-3150 Compared to Olmesartan in Patients With Essential Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Mineralocorticoid Receptor Antagonists</mesh_term>
	<mesh_term>Olmesartan</mesh_term>
	<mesh_term>Olmesartan Medoxomil</mesh_term>
	<criteria>Male and female subjects aged 20 years or older at informed consent Subjects with essential hypertension during runin period (mean 24hr systolic blood pressure SBP ≥ 130 and diastolic blood pressure DBP ≥ 80 mmHg and Sitting SBP ≥ 140 mmHg and &lt; 180 mmHg, Sitting DBP ≥ 90 mmHg and &lt; 110 mmHg) Secondary hypertension or malignant hypertension Diabetes mellitus with albuminuria Serum potassium level &lt; 3.5 or ≥ 5.1 mEq/L Reversed daynight life cycle including overnight workers eGFR &lt; 60 mL/min/1.73 m^2.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>essential hypertension</keyword>
	<keyword>mineralocorticoid receptor antagonist</keyword>
</DOC>